Global Long Non-coding RNA Sequencing (lncRNA-seq) Market Outlook, In‑Depth Analysis & Forecast to 2031

1 Study Coverage
1.1 Introduction to Long Non-coding RNA Sequencing (lncRNA-seq): Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Long Non-coding RNA Sequencing (lncRNA-seq) Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Equipment Supplies
1.2.3 Service
1.3 Market Segmentation by Application
1.3.1 Global Long Non-coding RNA Sequencing (lncRNA-seq) Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Developmental Biology
1.3.3 Oncology
1.3.4 Neuroscience
1.3.5 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Long Non-coding RNA Sequencing (lncRNA-seq) Revenue Estimates and Forecasts 2020-2031
2.2 Global Long Non-coding RNA Sequencing (lncRNA-seq) Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020-2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends
3 Competition by Players
3.1 Global Long Non-coding RNA Sequencing (lncRNA-seq) Player Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2020-2025)
3.1.2 Global Key Player Revenue Ranking (2023 vs. 2024)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Player (2020 VS 2024)
3.2 Global Long Non-coding RNA Sequencing (lncRNA-seq) Companies Headquarters and Service Footprint
3.3 Main Product Type Market Size by Players
3.3.1 Equipment Supplies Market Size by Players
3.3.2 Service Market Size by Players
3.4 Global Long Non-coding RNA Sequencing (lncRNA-seq) Market Concentration and Dynamics
3.4.1 Global Market Concentration (CR5 and HHI)
3.4.2 Entrant/Exit Impact Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Long Non-coding RNA Sequencing (lncRNA-seq) Revenue Trends by Type
4.1.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.1.2 Global Revenue Market Share by Type (2020-2031)
4.2 Key Product Attributes and Differentiation
4.3 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.3.1 High-Growth Niches and Adoption Drivers
4.3.2 Profitability Hotspots and Cost Drivers
4.3.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Long Non-coding RNA Sequencing (lncRNA-seq) Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.1.2 Revenue Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application
6 North America
6.1 North America Market Size (2020-2031)
6.2 North America Key Players Revenue in 2024
6.3 North America Long Non-coding RNA Sequencing (lncRNA-seq) Market Size by Type (2020-2031)
6.4 North America Long Non-coding RNA Sequencing (lncRNA-seq) Market Size by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Long Non-coding RNA Sequencing (lncRNA-seq) Market Size by Country
6.6.1 North America Revenue Trends by Country
6.6.2 US
6.6.3 Canada
6.6.4 Mexico
7 Europe
7.1 Europe Market Size (2020-2031)
7.2 Europe Key Players Revenue in 2024
7.3 Europe Long Non-coding RNA Sequencing (lncRNA-seq) Market Size by Type (2020-2031)
7.4 Europe Long Non-coding RNA Sequencing (lncRNA-seq) Market Size by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Long Non-coding RNA Sequencing (lncRNA-seq) Market Size by Country
7.6.1 Europe Revenue Trends by Country
7.6.2 Germany
7.6.3 France
7.6.4 U.K.
7.6.5 Italy
7.6.6 Russia
8 Asia-Pacific
8.1 Asia-Pacific Market Size (2020-2031)
8.2 Asia-Pacific Key Players Revenue in 2024
8.3 Asia-Pacific Long Non-coding RNA Sequencing (lncRNA-seq) Market Size by Type (2020-2031)
8.4 Asia-Pacific Long Non-coding RNA Sequencing (lncRNA-seq) Market Size by Application (2020-2031)
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Asia-Pacific Long Non-coding RNA Sequencing (lncRNA-seq) Market Size by Region
8.6.1 Asia-Pacific Revenue Trends by Region
8.7 China
8.8 Japan
8.9 South Korea
8.10 Australia
8.11 India
8.12 Southeast Asia
8.12.1 Indonesia
8.12.2 Vietnam
8.12.3 Malaysia
8.12.4 Philippines
8.12.5 Singapore
9 Central and South America
9.1 Central and South America Market Size (2020-2031)
9.2 Central and South America Key Players Revenue in 2024
9.3 Central and South America Long Non-coding RNA Sequencing (lncRNA-seq) Market Size by Type (2020-2031)
9.4 Central and South America Long Non-coding RNA Sequencing (lncRNA-seq) Market Size by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Long Non-coding RNA Sequencing (lncRNA-seq) Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Market Size (2020-2031)
10.2 Middle East and Africa Key Players Revenue in 2024
10.3 Middle East and Africa Long Non-coding RNA Sequencing (lncRNA-seq) Market Size by Type (2020-2031)
10.4 Middle East and Africa Long Non-coding RNA Sequencing (lncRNA-seq) Market Size by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Long Non-coding RNA Sequencing (lncRNA-seq) Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Israel
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Aksomics
11.1.1 Aksomics Corporation Information
11.1.2 Aksomics Business Overview
11.1.3 Aksomics Long Non-coding RNA Sequencing (lncRNA-seq) Product Features and Attributes
11.1.4 Aksomics Long Non-coding RNA Sequencing (lncRNA-seq) Revenue and Gross Margin (2020-2025)
11.1.5 Aksomics Long Non-coding RNA Sequencing (lncRNA-seq) Revenue by Product in 2024
11.1.6 Aksomics Long Non-coding RNA Sequencing (lncRNA-seq) Revenue by Application in 2024
11.1.7 Aksomics Long Non-coding RNA Sequencing (lncRNA-seq) Revenue by Geographic Area in 2024
11.1.8 Aksomics Long Non-coding RNA Sequencing (lncRNA-seq) SWOT Analysis
11.1.9 Aksomics Recent Developments
11.2 Anshengda
11.2.1 Anshengda Corporation Information
11.2.2 Anshengda Business Overview
11.2.3 Anshengda Long Non-coding RNA Sequencing (lncRNA-seq) Product Features and Attributes
11.2.4 Anshengda Long Non-coding RNA Sequencing (lncRNA-seq) Revenue and Gross Margin (2020-2025)
11.2.5 Anshengda Long Non-coding RNA Sequencing (lncRNA-seq) Revenue by Product in 2024
11.2.6 Anshengda Long Non-coding RNA Sequencing (lncRNA-seq) Revenue by Application in 2024
11.2.7 Anshengda Long Non-coding RNA Sequencing (lncRNA-seq) Revenue by Geographic Area in 2024
11.2.8 Anshengda Long Non-coding RNA Sequencing (lncRNA-seq) SWOT Analysis
11.2.9 Anshengda Recent Developments
11.3 BGI
11.3.1 BGI Corporation Information
11.3.2 BGI Business Overview
11.3.3 BGI Long Non-coding RNA Sequencing (lncRNA-seq) Product Features and Attributes
11.3.4 BGI Long Non-coding RNA Sequencing (lncRNA-seq) Revenue and Gross Margin (2020-2025)
11.3.5 BGI Long Non-coding RNA Sequencing (lncRNA-seq) Revenue by Product in 2024
11.3.6 BGI Long Non-coding RNA Sequencing (lncRNA-seq) Revenue by Application in 2024
11.3.7 BGI Long Non-coding RNA Sequencing (lncRNA-seq) Revenue by Geographic Area in 2024
11.3.8 BGI Long Non-coding RNA Sequencing (lncRNA-seq) SWOT Analysis
11.3.9 BGI Recent Developments
11.4 Annuoyouda Gene Technology
11.4.1 Annuoyouda Gene Technology Corporation Information
11.4.2 Annuoyouda Gene Technology Business Overview
11.4.3 Annuoyouda Gene Technology Long Non-coding RNA Sequencing (lncRNA-seq) Product Features and Attributes
11.4.4 Annuoyouda Gene Technology Long Non-coding RNA Sequencing (lncRNA-seq) Revenue and Gross Margin (2020-2025)
11.4.5 Annuoyouda Gene Technology Long Non-coding RNA Sequencing (lncRNA-seq) Revenue by Product in 2024
11.4.6 Annuoyouda Gene Technology Long Non-coding RNA Sequencing (lncRNA-seq) Revenue by Application in 2024
11.4.7 Annuoyouda Gene Technology Long Non-coding RNA Sequencing (lncRNA-seq) Revenue by Geographic Area in 2024
11.4.8 Annuoyouda Gene Technology Long Non-coding RNA Sequencing (lncRNA-seq) SWOT Analysis
11.4.9 Annuoyouda Gene Technology Recent Developments
11.5 LC Sciences
11.5.1 LC Sciences Corporation Information
11.5.2 LC Sciences Business Overview
11.5.3 LC Sciences Long Non-coding RNA Sequencing (lncRNA-seq) Product Features and Attributes
11.5.4 LC Sciences Long Non-coding RNA Sequencing (lncRNA-seq) Revenue and Gross Margin (2020-2025)
11.5.5 LC Sciences Long Non-coding RNA Sequencing (lncRNA-seq) Revenue by Product in 2024
11.5.6 LC Sciences Long Non-coding RNA Sequencing (lncRNA-seq) Revenue by Application in 2024
11.5.7 LC Sciences Long Non-coding RNA Sequencing (lncRNA-seq) Revenue by Geographic Area in 2024
11.5.8 LC Sciences Long Non-coding RNA Sequencing (lncRNA-seq) SWOT Analysis
11.5.9 LC Sciences Recent Developments
11.6 Creative Biolabs
11.6.1 Creative Biolabs Corporation Information
11.6.2 Creative Biolabs Business Overview
11.6.3 Creative Biolabs Long Non-coding RNA Sequencing (lncRNA-seq) Product Features and Attributes
11.6.4 Creative Biolabs Long Non-coding RNA Sequencing (lncRNA-seq) Revenue and Gross Margin (2020-2025)
11.6.5 Creative Biolabs Recent Developments
11.7 Eurofins Scientific
11.7.1 Eurofins Scientific Corporation Information
11.7.2 Eurofins Scientific Business Overview
11.7.3 Eurofins Scientific Long Non-coding RNA Sequencing (lncRNA-seq) Product Features and Attributes
11.7.4 Eurofins Scientific Long Non-coding RNA Sequencing (lncRNA-seq) Revenue and Gross Margin (2020-2025)
11.7.5 Eurofins Scientific Recent Developments
11.8 CD Genomics
11.8.1 CD Genomics Corporation Information
11.8.2 CD Genomics Business Overview
11.8.3 CD Genomics Long Non-coding RNA Sequencing (lncRNA-seq) Product Features and Attributes
11.8.4 CD Genomics Long Non-coding RNA Sequencing (lncRNA-seq) Revenue and Gross Margin (2020-2025)
11.8.5 CD Genomics Recent Developments
11.9 Novogene
11.9.1 Novogene Corporation Information
11.9.2 Novogene Business Overview
11.9.3 Novogene Long Non-coding RNA Sequencing (lncRNA-seq) Product Features and Attributes
11.9.4 Novogene Long Non-coding RNA Sequencing (lncRNA-seq) Revenue and Gross Margin (2020-2025)
11.9.5 Novogene Recent Developments
11.10 Beijing Compson Biotechnology Co., Ltd.
11.10.1 Beijing Compson Biotechnology Co., Ltd. Corporation Information
11.10.2 Beijing Compson Biotechnology Co., Ltd. Business Overview
11.10.3 Beijing Compson Biotechnology Co., Ltd. Long Non-coding RNA Sequencing (lncRNA-seq) Product Features and Attributes
11.10.4 Beijing Compson Biotechnology Co., Ltd. Long Non-coding RNA Sequencing (lncRNA-seq) Revenue and Gross Margin (2020-2025)
11.10.5 Company Ten Recent Developments
11.11 Biomark Biotechnology
11.11.1 Biomark Biotechnology Corporation Information
11.11.2 Biomark Biotechnology Business Overview
11.11.3 Biomark Biotechnology Long Non-coding RNA Sequencing (lncRNA-seq) Product Features and Attributes
11.11.4 Biomark Biotechnology Long Non-coding RNA Sequencing (lncRNA-seq) Revenue and Gross Margin (2020-2025)
11.11.5 Biomark Biotechnology Recent Developments
11.12 BD
11.12.1 BD Corporation Information
11.12.2 BD Business Overview
11.12.3 BD Long Non-coding RNA Sequencing (lncRNA-seq) Product Features and Attributes
11.12.4 BD Long Non-coding RNA Sequencing (lncRNA-seq) Revenue and Gross Margin (2020-2025)
11.12.5 BD Recent Developments
11.13 10x Genomics
11.13.1 10x Genomics Corporation Information
11.13.2 10x Genomics Business Overview
11.13.3 10x Genomics Long Non-coding RNA Sequencing (lncRNA-seq) Product Features and Attributes
11.13.4 10x Genomics Long Non-coding RNA Sequencing (lncRNA-seq) Revenue and Gross Margin (2020-2025)
11.13.5 10x Genomics Recent Developments
11.14 Majorbio
11.14.1 Majorbio Corporation Information
11.14.2 Majorbio Business Overview
11.14.3 Majorbio Long Non-coding RNA Sequencing (lncRNA-seq) Product Features and Attributes
11.14.4 Majorbio Long Non-coding RNA Sequencing (lncRNA-seq) Revenue and Gross Margin (2020-2025)
11.14.5 Majorbio Recent Developments
11.15 QIAGEN
11.15.1 QIAGEN Corporation Information
11.15.2 QIAGEN Business Overview
11.15.3 QIAGEN Long Non-coding RNA Sequencing (lncRNA-seq) Product Features and Attributes
11.15.4 QIAGEN Long Non-coding RNA Sequencing (lncRNA-seq) Revenue and Gross Margin (2020-2025)
11.15.5 QIAGEN Recent Developments
11.16 Roche
11.16.1 Roche Corporation Information
11.16.2 Roche Business Overview
11.16.3 Roche Long Non-coding RNA Sequencing (lncRNA-seq) Product Features and Attributes
11.16.4 Roche Long Non-coding RNA Sequencing (lncRNA-seq) Revenue and Gross Margin (2020-2025)
11.16.5 Roche Recent Developments
12 Long Non-coding RNA Sequencing (lncRNA-seq)Industry Chain Analysis
12.1 Long Non-coding RNA Sequencing (lncRNA-seq) Industry Chain
12.2 Upstream Analysis
12.2.1 Upstream Key Suppliers
12.3 Middlestream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Long Non-coding RNA Sequencing (lncRNA-seq) Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Long Non-coding RNA Sequencing (lncRNA-seq) Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details

List of Tables
Table 1. Global Long Non-coding RNA Sequencing (lncRNA-seq) Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Long Non-coding RNA Sequencing (lncRNA-seq) Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Long Non-coding RNA Sequencing (lncRNA-seq) Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Long Non-coding RNA Sequencing (lncRNA-seq) Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Long Non-coding RNA Sequencing (lncRNA-seq) Revenue by Region (2026-2031) & (US$ Million)
Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 7. Global Long Non-coding RNA Sequencing (lncRNA-seq) Revenue by Players (2020-2025) & (US$ Million)
Table 8. Global Long Non-coding RNA Sequencing (lncRNA-seq) Revenue Market Share by Players (2020-2025)
Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 10. Global Long Non-coding RNA Sequencing (lncRNA-seq) by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Long Non-coding RNA Sequencing (lncRNA-seq) as of 2024)
Table 11. Global Long Non-coding RNA Sequencing (lncRNA-seq) Average Gross Margin (%) by Player (2020 VS 2024)
Table 12. Global Long Non-coding RNA Sequencing (lncRNA-seq) Companies Headquarters
Table 13. Global Long Non-coding RNA Sequencing (lncRNA-seq) Market Concentration Ratio (CR5 and HHI)
Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 16. Global Long Non-coding RNA Sequencing (lncRNA-seq) Revenue by Type (2020-2025) & (US$ Million)
Table 17. Global Long Non-coding RNA Sequencing (lncRNA-seq) Revenue by Type (2026-2031) & (US$ Million)
Table 18. Key Product Attributes and Differentiation
Table 19. Global Long Non-coding RNA Sequencing (lncRNA-seq) Revenue by Application (2020-2025) & (US$ Million)
Table 20. Global Long Non-coding RNA Sequencing (lncRNA-seq) Revenue by Application (2026-2031) & (US$ Million)
Table 21. Long Non-coding RNA Sequencing (lncRNA-seq) High-Growth Sectors Demand CAGR (2024-2031)
Table 22. Top Customers by Region
Table 23. Top Customers by Application
Table 24. North America Long Non-coding RNA Sequencing (lncRNA-seq) Growth Accelerators and Market Barriers
Table 25. North America Long Non-coding RNA Sequencing (lncRNA-seq) Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 26. Europe Long Non-coding RNA Sequencing (lncRNA-seq) Growth Accelerators and Market Barriers
Table 27. Europe Long Non-coding RNA Sequencing (lncRNA-seq) Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 28. Asia-Pacific Long Non-coding RNA Sequencing (lncRNA-seq) Growth Accelerators and Market Barriers
Table 29. Asia-Pacific Long Non-coding RNA Sequencing (lncRNA-seq) Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 30. Central and South America Long Non-coding RNA Sequencing (lncRNA-seq) Investment Opportunities and Key Challenges
Table 31. Central and South America Long Non-coding RNA Sequencing (lncRNA-seq) Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 32. Middle East and Africa Long Non-coding RNA Sequencing (lncRNA-seq) Investment Opportunities and Key Challenges
Table 33. Middle East and Africa Long Non-coding RNA Sequencing (lncRNA-seq) Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 34. Aksomics Corporation Information
Table 35. Aksomics Description and Major Businesses
Table 36. Aksomics Product Features and Attributes
Table 37. Aksomics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 38. Aksomics Revenue Proportion by Product in 2024
Table 39. Aksomics Revenue Proportion by Application in 2024
Table 40. Aksomics Revenue Proportion by Geographic Area in 2024
Table 41. Aksomics Long Non-coding RNA Sequencing (lncRNA-seq) SWOT Analysis
Table 42. Aksomics Recent Developments
Table 43. Anshengda Corporation Information
Table 44. Anshengda Description and Major Businesses
Table 45. Anshengda Product Features and Attributes
Table 46. Anshengda Revenue (US$ Million) and Gross Margin (2020-2025)
Table 47. Anshengda Revenue Proportion by Product in 2024
Table 48. Anshengda Revenue Proportion by Application in 2024
Table 49. Anshengda Revenue Proportion by Geographic Area in 2024
Table 50. Anshengda Long Non-coding RNA Sequencing (lncRNA-seq) SWOT Analysis
Table 51. Anshengda Recent Developments
Table 52. BGI Corporation Information
Table 53. BGI Description and Major Businesses
Table 54. BGI Product Features and Attributes
Table 55. BGI Revenue (US$ Million) and Gross Margin (2020-2025)
Table 56. BGI Revenue Proportion by Product in 2024
Table 57. BGI Revenue Proportion by Application in 2024
Table 58. BGI Revenue Proportion by Geographic Area in 2024
Table 59. BGI Long Non-coding RNA Sequencing (lncRNA-seq) SWOT Analysis
Table 60. BGI Recent Developments
Table 61. Annuoyouda Gene Technology Corporation Information
Table 62. Annuoyouda Gene Technology Description and Major Businesses
Table 63. Annuoyouda Gene Technology Product Features and Attributes
Table 64. Annuoyouda Gene Technology Revenue (US$ Million) and Gross Margin (2020-2025)
Table 65. Annuoyouda Gene Technology Revenue Proportion by Product in 2024
Table 66. Annuoyouda Gene Technology Revenue Proportion by Application in 2024
Table 67. Annuoyouda Gene Technology Revenue Proportion by Geographic Area in 2024
Table 68. Annuoyouda Gene Technology Long Non-coding RNA Sequencing (lncRNA-seq) SWOT Analysis
Table 69. Annuoyouda Gene Technology Recent Developments
Table 70. LC Sciences Corporation Information
Table 71. LC Sciences Description and Major Businesses
Table 72. LC Sciences Product Features and Attributes
Table 73. LC Sciences Revenue (US$ Million) and Gross Margin (2020-2025)
Table 74. LC Sciences Revenue Proportion by Product in 2024
Table 75. LC Sciences Revenue Proportion by Application in 2024
Table 76. LC Sciences Revenue Proportion by Geographic Area in 2024
Table 77. LC Sciences Long Non-coding RNA Sequencing (lncRNA-seq) SWOT Analysis
Table 78. LC Sciences Recent Developments
Table 79. Creative Biolabs Corporation Information
Table 80. Creative Biolabs Description and Major Businesses
Table 81. Creative Biolabs Product Features and Attributes
Table 82. Creative Biolabs Revenue (US$ Million) and Gross Margin (2020-2025)
Table 83. Creative Biolabs Recent Developments
Table 84. Eurofins Scientific Corporation Information
Table 85. Eurofins Scientific Description and Major Businesses
Table 86. Eurofins Scientific Product Features and Attributes
Table 87. Eurofins Scientific Revenue (US$ Million) and Gross Margin (2020-2025)
Table 88. Eurofins Scientific Recent Developments
Table 89. CD Genomics Corporation Information
Table 90. CD Genomics Description and Major Businesses
Table 91. CD Genomics Product Features and Attributes
Table 92. CD Genomics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 93. CD Genomics Recent Developments
Table 94. Novogene Corporation Information
Table 95. Novogene Description and Major Businesses
Table 96. Novogene Product Features and Attributes
Table 97. Novogene Revenue (US$ Million) and Gross Margin (2020-2025)
Table 98. Novogene Recent Developments
Table 99. Beijing Compson Biotechnology Co., Ltd. Corporation Information
Table 100. Beijing Compson Biotechnology Co., Ltd. Description and Major Businesses
Table 101. Beijing Compson Biotechnology Co., Ltd. Product Features and Attributes
Table 102. Beijing Compson Biotechnology Co., Ltd. Revenue (US$ Million) and Gross Margin (2020-2025)
Table 103. Beijing Compson Biotechnology Co., Ltd. Recent Developments
Table 104. Biomark Biotechnology Corporation Information
Table 105. Biomark Biotechnology Description and Major Businesses
Table 106. Biomark Biotechnology Product Features and Attributes
Table 107. Biomark Biotechnology Revenue (US$ Million) and Gross Margin (2020-2025)
Table 108. Biomark Biotechnology Recent Developments
Table 109. BD Corporation Information
Table 110. BD Description and Major Businesses
Table 111. BD Product Features and Attributes
Table 112. BD Revenue (US$ Million) and Gross Margin (2020-2025)
Table 113. BD Recent Developments
Table 114. 10x Genomics Corporation Information
Table 115. 10x Genomics Description and Major Businesses
Table 116. 10x Genomics Product Features and Attributes
Table 117. 10x Genomics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 118. 10x Genomics Recent Developments
Table 119. Majorbio Corporation Information
Table 120. Majorbio Description and Major Businesses
Table 121. Majorbio Product Features and Attributes
Table 122. Majorbio Revenue (US$ Million) and Gross Margin (2020-2025)
Table 123. Majorbio Recent Developments
Table 124. QIAGEN Corporation Information
Table 125. QIAGEN Description and Major Businesses
Table 126. QIAGEN Product Features and Attributes
Table 127. QIAGEN Revenue (US$ Million) and Gross Margin (2020-2025)
Table 128. QIAGEN Recent Developments
Table 129. Roche Corporation Information
Table 130. Roche Description and Major Businesses
Table 131. Roche Product Features and Attributes
Table 132. Roche Revenue (US$ Million) and Gross Margin (2020-2025)
Table 133. Roche Recent Developments
Table 134. Raw Materials Key Suppliers
Table 135. Distributors List
Table 136. Market Trends and Market Evolution
Table 137. Market Drivers and Opportunities
Table 138. Market Challenges, Risks, and Restraints
Table 139. Research Programs/Design for This Report
Table 140. Key Data Information from Secondary Sources
Table 141. Key Data Information from Primary Sources


List of Figures
Figure 1. Long Non-coding RNA Sequencing (lncRNA-seq) Product Picture
Figure 2. Global Long Non-coding RNA Sequencing (lncRNA-seq) Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Equipment Supplies Product Picture
Figure 4. Service Product Picture
Figure 5. Global Long Non-coding RNA Sequencing (lncRNA-seq) Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 6. Developmental Biology
Figure 7. Oncology
Figure 8. Neuroscience
Figure 9. Other
Figure 10. Long Non-coding RNA Sequencing (lncRNA-seq) Report Years Considered
Figure 11. Global Long Non-coding RNA Sequencing (lncRNA-seq) Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 12. Global Long Non-coding RNA Sequencing (lncRNA-seq) Revenue (2020-2031) & (US$ Million)
Figure 13. Global Long Non-coding RNA Sequencing (lncRNA-seq) Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 14. Global Long Non-coding RNA Sequencing (lncRNA-seq) Revenue Market Share by Region (2020-2031)
Figure 15. Global Long Non-coding RNA Sequencing (lncRNA-seq) Revenue Market Share Ranking (2024)
Figure 16. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 17. Equipment Supplies Revenue Market Share by Player in 2024
Figure 18. Service Revenue Market Share by Player in 2024
Figure 19. Global Long Non-coding RNA Sequencing (lncRNA-seq) Revenue Market Share by Type (2020-2031)
Figure 20. Global Long Non-coding RNA Sequencing (lncRNA-seq) Revenue Market Share by Application (2020-2031)
Figure 21. North America Long Non-coding RNA Sequencing (lncRNA-seq) Revenue YoY (2020-2031) & (US$ Million)
Figure 22. North America Top 5 Players Long Non-coding RNA Sequencing (lncRNA-seq) Revenue (US$ Million) in 2024
Figure 23. North America Long Non-coding RNA Sequencing (lncRNA-seq) Revenue (US$ Million) by Type (2020 - 2031)
Figure 24. North America Long Non-coding RNA Sequencing (lncRNA-seq) Revenue (US$ Million) by Application (2020-2031)
Figure 25. US Long Non-coding RNA Sequencing (lncRNA-seq) Revenue (2020-2031) & (US$ Million)
Figure 26. Canada Long Non-coding RNA Sequencing (lncRNA-seq) Revenue (2020-2031) & (US$ Million)
Figure 27. Mexico Long Non-coding RNA Sequencing (lncRNA-seq) Revenue (2020-2031) & (US$ Million)
Figure 28. Europe Long Non-coding RNA Sequencing (lncRNA-seq) Revenue YoY (2020-2031) & (US$ Million)
Figure 29. Europe Top 5 Players Long Non-coding RNA Sequencing (lncRNA-seq) Revenue (US$ Million) in 2024
Figure 30. Europe Long Non-coding RNA Sequencing (lncRNA-seq) Revenue (US$ Million) by Type (2020-2031)
Figure 31. Europe Long Non-coding RNA Sequencing (lncRNA-seq) Revenue (US$ Million) by Application (2020-2031)
Figure 32. Germany Long Non-coding RNA Sequencing (lncRNA-seq) Revenue (2020-2031) & (US$ Million)
Figure 33. France Long Non-coding RNA Sequencing (lncRNA-seq) Revenue (2020-2031) & (US$ Million)
Figure 34. U.K. Long Non-coding RNA Sequencing (lncRNA-seq) Revenue (2020-2031) & (US$ Million)
Figure 35. Italy Long Non-coding RNA Sequencing (lncRNA-seq) Revenue (2020-2031) & (US$ Million)
Figure 36. Russia Long Non-coding RNA Sequencing (lncRNA-seq) Revenue (2020-2031) & (US$ Million)
Figure 37. Asia-Pacific Long Non-coding RNA Sequencing (lncRNA-seq) Revenue YoY (2020-2031) & (US$ Million)
Figure 38. Asia-Pacific Top 8 Players Long Non-coding RNA Sequencing (lncRNA-seq) Revenue (US$ Million) in 2024
Figure 39. Asia-Pacific Long Non-coding RNA Sequencing (lncRNA-seq) Revenue (US$ Million) by Type (2020-2031)
Figure 40. Asia-Pacific Long Non-coding RNA Sequencing (lncRNA-seq) Revenue (US$ Million) by Application (2020-2031)
Figure 41. Indonesia Long Non-coding RNA Sequencing (lncRNA-seq) Revenue (2020-2031) & (US$ Million)
Figure 42. Japan Long Non-coding RNA Sequencing (lncRNA-seq) Revenue (2020-2031) & (US$ Million)
Figure 43. South Korea Long Non-coding RNA Sequencing (lncRNA-seq) Revenue (2020-2031) & (US$ Million)
Figure 44. Australia Long Non-coding RNA Sequencing (lncRNA-seq) Revenue (2020-2031) & (US$ Million)
Figure 45. India Long Non-coding RNA Sequencing (lncRNA-seq) Revenue (2020-2031) & (US$ Million)
Figure 46. Indonesia Long Non-coding RNA Sequencing (lncRNA-seq) Revenue (2020-2031) & (US$ Million)
Figure 47. Vietnam Long Non-coding RNA Sequencing (lncRNA-seq) Revenue (2020-2031) & (US$ Million)
Figure 48. Malaysia Long Non-coding RNA Sequencing (lncRNA-seq) Revenue (2020-2031) & (US$ Million)
Figure 49. Philippines Long Non-coding RNA Sequencing (lncRNA-seq) Revenue (2020-2031) & (US$ Million)
Figure 50. Singapore Long Non-coding RNA Sequencing (lncRNA-seq) Revenue (2020-2031) & (US$ Million)
Figure 51. Central and South America Long Non-coding RNA Sequencing (lncRNA-seq) Revenue YoY (2020-2031) & (US$ Million)
Figure 52. Central and South America Top 5 Players Long Non-coding RNA Sequencing (lncRNA-seq) Revenue (US$ Million) in 2024
Figure 53. Central and South America Long Non-coding RNA Sequencing (lncRNA-seq) Revenue (US$ Million) by Type (2020-2031)
Figure 54. Central and South America Long Non-coding RNA Sequencing (lncRNA-seq) Revenue (US$ Million) by Application (2020-2031)
Figure 55. Brazil Long Non-coding RNA Sequencing (lncRNA-seq) Revenue (2020-2025) & (US$ Million)
Figure 56. Argentina Long Non-coding RNA Sequencing (lncRNA-seq) Revenue (2020-2025) & (US$ Million)
Figure 57. Middle East and Africa Long Non-coding RNA Sequencing (lncRNA-seq) Revenue YoY (2020-2031) & (US$ Million)
Figure 58. Middle East and Africa Top 5 Players Long Non-coding RNA Sequencing (lncRNA-seq) Revenue (US$ Million) in 2024
Figure 59. South America Long Non-coding RNA Sequencing (lncRNA-seq) Revenue (US$ Million) by Type (2020-2031)
Figure 60. Middle East and Africa Long Non-coding RNA Sequencing (lncRNA-seq) Revenue (US$ Million) by Application (2020-2031)
Figure 61. GCC Countries Long Non-coding RNA Sequencing (lncRNA-seq) Revenue (2020-2025) & (US$ Million)
Figure 62. Israel Long Non-coding RNA Sequencing (lncRNA-seq) Revenue (2020-2025) & (US$ Million)
Figure 63. Egypt Long Non-coding RNA Sequencing (lncRNA-seq) Revenue (2020-2025) & (US$ Million)
Figure 64. South Africa Long Non-coding RNA Sequencing (lncRNA-seq) Revenue (2020-2025) & (US$ Million)
Figure 65. Long Non-coding RNA Sequencing (lncRNA-seq) Industry Chain Mapping
Figure 66. Channels of Distribution (Direct Vs Distribution)
Figure 67. Bottom-up and Top-down Approaches for This Report
Figure 68. Data Triangulation
Figure 69. Key Executives Interviewed

Your Name

Your E-mail

Your message

Submit